US 12,338,285 B2
Anti-FcRn antibodies
Helene Margaret Finney, Slough (GB); Alastair David Griffiths Lawson, Slough (GB); Stevan Graham Shaw, Slough (GB); Bryan John Smith, Slough (GB); Kerry Louise Tyson, Slough (GB); Lara Kevorkian, Slough (GB); Christoph Meier, Slough (GB); Kaushik Sarkar, Slough (GB); and Paul Alan Atherfold, Slough (GB)
Assigned to UCB BIOPHARMA SRL, Brussels (BE)
Filed by UCB Biopharma SRL, Brussels (BE)
Filed on Jun. 1, 2022, as Appl. No. 17/804,934.
Application 17/804,934 is a division of application No. 16/271,086, filed on Feb. 8, 2019, granted, now 11,384,148, issued on Jul. 12, 2022.
Application 16/271,086 is a division of application No. 14/400,812, granted, now 10,233,243, issued on Mar. 19, 2019, previously published as PCT/EP2013/059802, filed on May 13, 2013.
Claims priority of application No. 1208370 (GB), filed on May 14, 2012.
Prior Publication US 2023/0074381 A1, Mar. 9, 2023
Int. Cl. C07H 21/02 (2006.01); A61K 39/395 (2006.01); A61K 47/60 (2017.01); A61K 47/64 (2017.01); C07K 16/28 (2006.01); C12N 1/20 (2006.01); C12N 5/02 (2006.01); C12P 21/06 (2006.01); G01N 33/50 (2006.01); G01N 33/564 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01)
CPC C07K 16/283 (2013.01) [A61K 39/3955 (2013.01); A61K 47/60 (2017.08); A61K 47/643 (2017.08); G01N 33/5047 (2013.01); G01N 33/564 (2013.01); G01N 33/6854 (2013.01); G01N 33/6857 (2013.01); G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70535 (2013.01); G01N 2500/02 (2013.01); G01N 2500/10 (2013.01); G01N 2800/104 (2013.01); G01N 2800/24 (2013.01); G01N 2800/28 (2013.01)] 52 Claims
 
1. An isolated DNA molecule or a pair of isolated DNA molecules encoding the heavy and light chains of an anti-FcRn antibody or FcRn-binding fragment thereof, wherein
the heavy chain comprises three CDRs, wherein CDR H1 has the sequence given in SEQ ID NO: 1, CDR H2 has the sequence given in SEQ ID NO: 2, and CDR H3 has the sequence given in SEQ ID NO: 3, and
the light chain comprises three CDRs, wherein CDR L1 has the sequence given in SEQ ID NO: 4, CDR L2 has the sequence given in SEQ ID NO: 5 and CDR L3 has the sequence given in SEQ ID NO: 6.